Analysts Expect Capital Southwest Co. (NASDAQ:CSWC) Will Post Quarterly Sales of $15.61 Million

Share on StockTwits

Brokerages predict that Capital Southwest Co. (NASDAQ:CSWC) will post sales of $15.61 million for the current quarter, according to Zacks. Three analysts have made estimates for Capital Southwest’s earnings, with estimates ranging from $15.09 million to $15.91 million. Capital Southwest posted sales of $13.87 million during the same quarter last year, which would indicate a positive year over year growth rate of 12.5%. The company is expected to report its next earnings report on Monday, February 3rd.

On average, analysts expect that Capital Southwest will report full year sales of $62.63 million for the current financial year, with estimates ranging from $61.89 million to $63.49 million. For the next financial year, analysts expect that the business will report sales of $69.57 million, with estimates ranging from $68.69 million to $70.60 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Capital Southwest.

Capital Southwest (NASDAQ:CSWC) last announced its earnings results on Tuesday, November 5th. The asset manager reported $0.38 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.43 by ($0.05). Capital Southwest had a return on equity of 8.53% and a net margin of 44.96%. The business had revenue of $15.22 million for the quarter, compared to analysts’ expectations of $15.28 million.

CSWC has been the subject of several recent analyst reports. ValuEngine raised Capital Southwest from a “sell” rating to a “hold” rating in a report on Tuesday. BidaskClub upgraded shares of Capital Southwest from a “sell” rating to a “hold” rating in a report on Saturday, November 30th. Zacks Investment Research lowered shares of Capital Southwest from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. National Securities assumed coverage on shares of Capital Southwest in a research report on Monday, September 23rd. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on shares of Capital Southwest in a research note on Thursday, October 10th. They issued a “buy” rating and a $24.00 target price for the company. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $23.40.

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC lifted its holdings in shares of Capital Southwest by 656.0% during the third quarter. Millennium Management LLC now owns 231,542 shares of the asset manager’s stock worth $5,047,000 after purchasing an additional 200,916 shares during the period. Creative Planning boosted its holdings in shares of Capital Southwest by 591.2% in the 3rd quarter. Creative Planning now owns 129,074 shares of the asset manager’s stock valued at $2,814,000 after acquiring an additional 110,399 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of Capital Southwest in the second quarter worth $2,124,000. Russell Investments Group Ltd. increased its stake in shares of Capital Southwest by 74.1% in the second quarter. Russell Investments Group Ltd. now owns 60,977 shares of the asset manager’s stock worth $1,277,000 after acquiring an additional 25,955 shares during the period. Finally, Citadel Advisors LLC raised its holdings in shares of Capital Southwest by 150.5% during the second quarter. Citadel Advisors LLC now owns 35,220 shares of the asset manager’s stock worth $738,000 after purchasing an additional 21,161 shares during the last quarter. 45.16% of the stock is owned by institutional investors.

Capital Southwest stock traded up $0.01 during midday trading on Tuesday, reaching $22.05. The company’s stock had a trading volume of 149,093 shares, compared to its average volume of 75,424. The stock’s 50-day simple moving average is $21.72 and its 200-day simple moving average is $21.64. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.29 and a quick ratio of 0.29. Capital Southwest has a 52-week low of $17.22 and a 52-week high of $22.90. The stock has a market capitalization of $395.36 million, a P/E ratio of 15.53 and a beta of 0.18.

About Capital Southwest

Capital Southwest Corporation is a business development company specializing in credit and private equity and venture capital investments in middle market companies, mezzanine, later stage, mature, late venture, emerging growth, buyouts, recapitalizations and growth capital investments. It does not invest in startups, publicly traded companies, real estate developments, project finance opportunities, oil and gas exploration businesses, troubled companies, turnarounds, and companies in which significant senior management is departing.

Further Reading: How analysts view the yield curve

Get a free copy of the Zacks research report on Capital Southwest (CSWC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Capital Southwest (NASDAQ:CSWC)

Receive News & Ratings for Capital Southwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capital Southwest and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

QuickLogic  Downgraded by Zacks Investment Research to Sell
QuickLogic Downgraded by Zacks Investment Research to Sell
Regeneron Pharmaceuticals  Upgraded to “Buy” by BidaskClub
Regeneron Pharmaceuticals Upgraded to “Buy” by BidaskClub
Proofpoint  Raised to “Buy” at BidaskClub
Proofpoint Raised to “Buy” at BidaskClub
Omeros  Upgraded at BidaskClub
Omeros Upgraded at BidaskClub
360 Finance  Rating Increased to Buy at ValuEngine
360 Finance Rating Increased to Buy at ValuEngine
Kiniksa Pharmaceuticals  Downgraded by Zacks Investment Research to “Sell”
Kiniksa Pharmaceuticals Downgraded by Zacks Investment Research to “Sell”


 
© 2006-2020 Zolmax.